R1 RCM (RCM) Downgraded by Zacks Investment Research to Sell
Zacks Investment Research cut shares of R1 RCM (NASDAQ:RCM) from a hold rating to a sell rating in a report released on Friday morning.
According to Zacks, “R1 RCM Inc. offers financial services for the health care industries. The Company provides revenue cycle management and physician advisory services, as well as transforms and manages the commercial infrastructure of health care organizations. R1 RCM Inc., formerly known as Accretive Health, Inc., is headquartered in Chicago, Illinois. “
A number of other analysts have also recently commented on RCM. BidaskClub upgraded shares of R1 RCM from a hold rating to a buy rating in a research note on Thursday, August 30th. Cantor Fitzgerald lifted their target price on shares of R1 RCM from $10.00 to $11.00 and gave the stock an overweight rating in a research note on Friday, August 10th. TheStreet upgraded shares of R1 RCM from a d+ rating to a c rating in a research note on Tuesday, September 4th. Finally, Chardan Capital began coverage on shares of R1 RCM in a research note on Tuesday, September 4th. They issued a buy rating and a $17.00 target price for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. R1 RCM currently has an average rating of Buy and a consensus price target of $11.05.
R1 RCM (NASDAQ:RCM) last issued its quarterly earnings data on Wednesday, November 7th. The financial services provider reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.12). R1 RCM had a negative return on equity of 132.32% and a negative net margin of 10.70%. The firm had revenue of $250.40 million during the quarter, compared to analysts’ expectations of $240.09 million. During the same period in the previous year, the firm earned ($0.08) EPS. The firm’s quarterly revenue was up 103.2% on a year-over-year basis. On average, equities research analysts expect that R1 RCM will post -0.18 earnings per share for the current fiscal year.
In other R1 RCM news, Director Charles J. Ditkoff sold 20,635 shares of R1 RCM stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $8.47, for a total transaction of $174,778.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Albert Rene Zimmerli acquired 10,000 shares of the firm’s stock in a transaction on Thursday, September 6th. The shares were acquired at an average price of $9.73 per share, with a total value of $97,300.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at approximately $97,300. The disclosure for this purchase can be found here. 59.40% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Penn Capital Management Co. Inc. lifted its stake in R1 RCM by 23.9% during the 3rd quarter. Penn Capital Management Co. Inc. now owns 1,477,994 shares of the financial services provider’s stock valued at $16,321,000 after acquiring an additional 285,064 shares during the period. TIAA CREF Investment Management LLC lifted its stake in R1 RCM by 32.1% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 749,953 shares of the financial services provider’s stock valued at $7,620,000 after acquiring an additional 182,332 shares during the period. Neuberger Berman Group LLC lifted its stake in R1 RCM by 112.3% during the 3rd quarter. Neuberger Berman Group LLC now owns 262,679 shares of the financial services provider’s stock valued at $2,669,000 after acquiring an additional 138,957 shares during the period. AQR Capital Management LLC lifted its stake in R1 RCM by 15.5% during the 3rd quarter. AQR Capital Management LLC now owns 76,482 shares of the financial services provider’s stock valued at $777,000 after acquiring an additional 10,286 shares during the period. Finally, MetLife Investment Advisors LLC lifted its stake in R1 RCM by 57.5% during the 3rd quarter. MetLife Investment Advisors LLC now owns 74,057 shares of the financial services provider’s stock valued at $752,000 after acquiring an additional 27,031 shares during the period. Institutional investors and hedge funds own 54.08% of the company’s stock.
About R1 RCM
R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers.
See Also: What are Institutional Investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.